Demystifying Investing in the HealthTech Sector – South Australia

Investor-only Workshop 2022

It is our pleasure to invite you to MTPConnect REDI Demystifying Investing in the HealthTech Sector workshop and networking event for investors.

Join us in Adelaide on Tuesday 26 July for a 2.5-hour in-person workshop followed by networking. Meet and connect with other healthtech investment specialists and investors.

Registration opens at 2:00pm for a 2:30pm start.

Why attend?

• Hear from investors and experts in the Medtech, Biotech and Pharmaceutical (MTP) sector
• Improve your knowledge about the benefits and risks of investing in MTP companies
• Learn to assess investment opportunities
• Meet with fellow investors and grow your network

The event is open to all investors seeking to increase their knowledge of the MTP sector and is free of charge.

Seats are strictly limited and for investors-only.

Agenda:

• 2:00pm - Registration
• 2:30-3:55pm - Workshop: Rob McInnes and Richard Dale, Sydney Angels
• 3:55-4:10pm - Break
• 4:10-5:00pm - Panel Discussion including Dr Leanna Read, Southern Angels; Kirsten Bernhardt, Artesian; and Stephanie Morris, Adelaide Intermediary Program, MTPConnect
• 5:00-6:00pm - Networking and canapés

About the speakers:

Rob McInnes is a Committee member of Sydney Angels, and the Principal of his solo law practice Rob McInnes IP Advisory, which he founded after working for 30 years in large law and patent attorney firms. He specialises in IP transactions and advises clients on the management and commercialisation of IP rights and due diligence on the IP positions of technology start-ups.

Rob holds a degree in chemistry and has been an in-house Manager of IP and Technology Transfer with a multinational company. He is an active angel investor with more than 20 portfolio companies, a Limited Partner in several VC funds, and a volunteer mentor at a number of start-up programs.

For the past decade Rob has been ranked as Australia’s most highly recommended patent and technology licensing lawyer, but these days he is trying to do less law and more investing.

Richard Dale is based in Sydney and has more than 30 years’ experience in top-tier management consulting, new venture development, venture capital, and R&D engineering. Since 2005 he has been a self-employed independent licensed adviser (Dale Advisers Pty Ltd AFSL 298916), providing strategy and funding solutions to Australian technology companies, from spinouts and startups, up to medium-size private companies with global opportunities.

As Partner NSW Universities for Campus Plus Pty Ltd, Richard also helps universities with their commercialisation process and projects, including spin-outs, and researcher and industry engagement.

Richard is heavily involved in the start-up ecosystem in a pro-bono capacity as co-founder and committee member of Sydney Angels, an angel group established in 2008. Its 120 members invest through a team-based process in innovative early-stage companies with high growth potential (83 to date, $33M directly invested, attracting a further $460M). Early-stage investments in medical technology startups include Atomo Diagnostics and Clarity Pharmaceuticals, both now ASX listed companies.

Richard holds a Bachelor of Engineering with 1st Class Honours from the University of Western Australia, and an MBA from London Business School.

Dr Leanna Read, BAgSc(Hons), PhD, FAICD, FTSE, has broad-ranging research, company executive, board and investment experience in technology-based enterprises, particularly biotechnology, including founding a successful company, TGR BioSciences Pty Ltd. She currently chairs biotech companies, TekCyte Ltd and Carina Biotech Pty Ltd, and is a board member of Biosensis Pty Ltd, and the Federal Government Biomedical Translation Fund Committee. Leanna is a foundational member of Southern Angels and a board member of Uniseed Venture Capital. Previous roles include SA Chief Scientist, Chair and CEO of the CRC for Cell Therapy Manufacturing, and Member of the Commercialisation Australia Board.

Kirsten Bernhardt is a venture capital investor with Artesian, an early-stage VC Fund which manages the South Australian Venture Capital Fund. Kirsten has a passion for high growth technology start-ups and is a strong advocate for supporting women in technology and finance. Prior to joining Artesian, Kirsten spent time in San Francisco, working as an operator in strategic finance for a venture backed SaaS company. She also worked in technology banking, advising a portfolio of software, ecommerce, and online gaming clients on debt transactions up to $2bn. Before moving to the US, Kirsten worked in technology commercialisation – Life Sciences, for the University of Adelaide, and started her career in Corporate Finance with Big 4 firms KPMG and EY.

Kirsten holds a Bachelor of Commerce from the University of Adelaide and is a member of Chartered Accountants Australia & New Zealand, and the Australian Institute of Company Directors.

Stephanie Morris is Director Innovation and Translation for the Adelaide Intermediary Program at MTPConnect and is a life-sciences professional with enthusiasm for medical technology commercialisation. Her expertise extends across collaborative research with industry, invention, IP protection, licensing, spin-out formation, investment, and venture creation. Most recently, Stephanie led the industry partnerships and translational activities for academic discovery and innovation at Imperial College London’s Faculty of Medicine in the UK, a world top 10 university, where she continues as an expert consultant.

Stephanie’s experience spans over 20 years in the sector, having worked within start-up companies and SMEs to large multinational pharmaceutical organisations at operational and governance levels. She brings dexterity from across the full care continuum, including academia, R&D, clinical development, commercialisation, as well as working with patients in both acute and chronic settings in the community.

Stephanie is also Deputy Chair for Cure4CF Foundation, a not-for-profit organisation driven to find a cure for cystic fibrosis. She holds an MBA from the University of South Australia, is a Graduate of the Australian Institute of Company Directors, a Certified Licensing Professional, and has graduate qualifications in both Business and Biomedical Science.

For further information please get in touch with Jarrod Belcher, Director REDI Initiative, on +61 402 456 301 or at REDI@mtpconnect.org.au.

DISCLAIMER: The material in this workshop is intended to provide a general summary only and should not be relied on as a substitute for legal or other professional advice. You should obtain your own legal or other professional advice.